Bioventus Inc.
8.86
-0.30 (-3.28%)
At close: Jan 14, 2025, 3:59 PM
8.28
-6.57%
After-hours Jan 14, 2025, 05:32 PM EST
undefined%
Bid 8.01
Market Cap 579.16M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.6
PE Ratio (ttm) -14.77
Forward PE n/a
Analyst Strong Buy
Ask 9.7
Volume 244,242
Avg. Volume (20D) 377,475
Open 9.18
Previous Close 9.16
Day's Range 8.84 - 9.31
52-Week Range 3.90 - 14.38
Beta undefined

About BVS

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones,...

Sector Healthcare
IPO Date Feb 11, 2021
Employees 1,030
Stock Exchange NASDAQ
Ticker Symbol BVS

Analyst Forecast

According to 3 analyst ratings, the average rating for BVS stock is "Strong Buy." The 12-month stock price forecast is $15, which is an increase of 69.30% from the latest price.

Buy 66.67%
Hold 33.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Bioventus Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of $144.83M, reflecting a 6.95% YoY growth and earnings per share of 0.08, making a 14.29% increase YoY.
2 months ago · Source
-16.27%
Bioventus shares are trading lower. The company re... Unlock content with Pro Subscription
3 months ago · Source
+5.34%
Bioventus shares are trading higher after Craig-Hallum maintained a Buy rating on the stock and raised its price target from $12 to $17.